Drug Profile
Lisdexamfetamine - Shionogi/Takeda
Alternative Names: Elvanse; Elvanse Adult; LDX; Lisdexamfetamine dimesilate; Lisdexamfetamine dimesylate; NRP-104; S-877489; SHP 489; SPD-489; Tyvense; Venvanse; VyvanseLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator New River Pharmaceuticals
- Developer Lindner Center of HOPE; Shionogi; Shire; Takeda
- Class Amides; Amphetamines; Antipsychotics; Behavioural disorder therapies; Drug withdrawal therapies; Neuropsychotherapeutics; Sleep disorder therapies; Small molecules
- Mechanism of Action Adrenergic uptake inhibitors; Dopamine uptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Attention-deficit hyperactivity disorder; Eating disorders
- Phase II Mood disorders
- Discontinued Bipolar depression; Cocaine-related disorders; Major depressive disorder; Schizophrenia; Sleep disorders
Most Recent Events
- 31 Oct 2022 Takeda and Shionogi terminate the license agreement for co-development and co-promotion for lisdexamfetamine in Japan
- 03 Dec 2019 Launched for Attention-deficit hyperactivity disorder (In adolescents, In children) in Japan (PO)
- 10 Jul 2019 Registered for Attention-deficit hyperactivity disorder (In children) in Canada (PO, Tablet)